Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea

Rosso, J.Q. Del; Webster, Guy F.; Jackson, Mark; Rendon, Marta; Rich, Phoebe; Torok, Helen; Bradshaw, Mark

doi:10.1016/j.jaad.2006.11.021

Cited by 186 publications

(212 citation statements)

References 34 publications

(60 reference statements)

Supporting

Mentioning

183

Contrasting

Unclassified

Order By: Relevance

“…Rosacea is treated with 30 mg of immediate release and 10 mg of delayed release beads of doxycycline (Oracea). Some studies using either 20 mg twice daily (Bikowski, 2003;Thiboutot et al, 2009) or 40 mg once daily (Del Rosso et al, 2007) for the treatment of rosacea reported no adverse events. The comparison of 100 versus 40 mg of doxycycline once daily for the treatment of rosacea revealed significant fewer adverse events in the 40-mg group (Del Rosso et al, 2008).…”

Section: Discussionmentioning

confidence: 99%

“…Doxycycline, given in a subantimicrobal dose, is also the only MMP inhibitor approved by the U.S. Food and Drug Administration. It is currently used for the treatment of periodontal disease (Wennström et al, 2001) and rosacea (Del Rosso et al, 2007). We hypothesized that MMP inhibition in the mouse experimental model of vEDS would shift the balance between collagen degradation and synthesis in the vascular wall and protect against vascular damage.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Doxycycline Ameliorates the Susceptibility to Aortic Lesions in a Mouse Model for the Vascular Type of Ehlers-Danlos Syndrome

Briest¹,

Cooper²,

Tae³

et al. 2011

J Pharmacol Exp Ther

View full text Add to dashboard Cite

The vascular form of Ehlers-Danlos syndrome (vEDS), a rare disease with grave complications resulting from rupture of major arteries, is caused by mutations of collagen type III [␣1 chain of collagen type III (COL3A1)]. The only, recently proven, preventive strategy consists of the reduction of arterial wall stress by ␤-adrenergic blockers. The heterozygous (HT) Col3a1 knockout mouse has reduced expression of collagen III and recapitulates features of a mild presentation of the disease. The objective of this study was to determine whether changing the balance between synthesis and degradation of collagen by chronic treatment with doxycycline, a nonspecific matrix metalloproteinase (MMP) inhibitor, could prevent the development of vascular pathology in HT mice. After 3 months of treatment with doxycycline or placebo, 9-month-old HT or wild-type (WT) mice were subjected to surgical stressing of the aorta. A 3-fold increase in stress-induced aortic lesions found in untreated HT mice 1 week after intervention (cumulative score 4.5 Ϯ 0.87 versus 1.3 Ϯ 0.34 in WT, p Ͻ 0.001) was fully prevented in the doxycycline-treated group (1.1 Ϯ 0.56, p Ͻ 0.001). Untreated HT mice showed increased MMP-9 activity in the carotid artery and decreased collagen content in the aorta; however, in doxycycline-treated animals there was normalization to the levels observed in WT mice. Doxycycline treatment inhibits the activity of tissue MMP and attenuates the decrease in the collagen content in aortas of mice haploinsufficient for collagen III, as well as prevents the development of stress-induced vessel pathology. The results suggest that doxycycline merits clinical testing as a treatment for vEDS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Doxycycline Ameliorates the Susceptibility to Aortic Lesions in a Mouse Model for the Vascular Type of Ehlers-Danlos Syndrome

Briest¹,

Cooper²,

Tae³

et al. 2011

J Pharmacol Exp Ther

View full text Add to dashboard Cite

show abstract

“…The formulation allows for immediate release of 30 mg with delayed release of 10 mg once ingested. 48 Through inhibition of numerous matrix metalloproteinases, a reduction in the quantity and activity of serine protease kallikrein 5 results in decreased production of cathelicidin LL-37, the same AMP that has been highlighted in the pathogenesis of rosacea. 49 Key anti-inflammatory actions of doxycycline in rosacea include: downregulation of cytokines, reducing neutrophil infiltration, inhibition of nitric oxide and its vasodilatory effects, reduction of reactive oxygen species, slowing connective tissue destruction, and inhibition of matrix metalloproteinases.…”

Section: Systemic Therapiesmentioning

confidence: 95%

Update on the Management of Rosacea

Weinkle

Doktor

Emer

2015

Plastic Surgical Nursing

View full text Add to dashboard Cite

Abstract:Refining diagnostic criteria has identified key characteristics differentiating rosacea, a chronic skin disorder, from other common cutaneous inflammatory conditions. The current classification system developed by the National Rosacea Society Expert Committee consists of erythematotelangiectatic, papulopustular, phymatous, and ocular subtypes. Each subtype stands as a unique entity among a spectrum, with characteristic symptoms and physical findings, along with an intricate pathophysiology. The main treatment modalities for rosacea include topical, systemic, laser, and light therapies. Topical brimonidine tartrate gel and calcineurin inhibitors are at the forefront of topical therapies, alone or in combination with traditional therapies such as topical metronidazole or azelaic acid and oral tetracyclines or isotretinoin. Vascular laser and intense pulsed light therapies are beneficial for the erythema and telangiectasia, as well as the symptoms (itching, burning, pain, stinging, swelling) of rosacea. Injectable botulinum toxin, topical ivermectin, and microsecond long-pulsed neodymium-yttrium aluminum garnet laser are emerging therapies that may prove to be extremely beneficial in the future. Once a debilitating disorder, rosacea has become a well known and manageable entity in the setting of numerous emerging therapeutic options. Herein, we describe the treatments currently available and give our opinions regarding emerging and combination therapies.

show abstract

“…Second-generation tetracyclines, such as minocycline and doxycycline, are also effective and offer the advantages of once daily administration and less gastrointestinal side effects [24]. Doxycycline shows anti-inflammatory effects at doses as low as 40 mg daily [29]. Azithromycin was proven to be as effective as doxycycline in a number of studies [4].…”

Section: Papulopustular Rosaceamentioning

confidence: 99%

Acne Rosacea

Engın¹,

Oba²,

Kutlubay³

et al. 2017

Acne and Acneiform Eruptions

View full text Add to dashboard Cite

Rosacea is a common chronic inflammatory cutaneous disorder with variable presentation and severity. Disease usually occurs between the ages of 30 and 50 years. Women are more commonly affected than men. Rosacea is divided into four subtypes: erythematotelangiectatic, papulopustular, phymatous, and ocular, and one variant: lupoid or granulomatous rosacea. Erythematotelangiectatic rosacea is manifested as flushing and persistent centrofacial erythema, and papulopustular rosacea as papules and pustules in a centrofacial distribution. With disease progression, phymas consisting of sebaceous gland hypertrophy can develop. Ocular rosacea can result in blepharitis and conjunctivitis. Diagnosis is made clinically. Management of rosacea consists of protective measures such as sun protection and gentle skin care and topical and systemic treatments to suppress inflammation and erythema.

show abstract

Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea

Cited by 186 publications

References 34 publications

Doxycycline Ameliorates the Susceptibility to Aortic Lesions in a Mouse Model for the Vascular Type of Ehlers-Danlos Syndrome

Doxycycline Ameliorates the Susceptibility to Aortic Lesions in a Mouse Model for the Vascular Type of Ehlers-Danlos Syndrome

Update on the Management of Rosacea

Acne Rosacea

Contact Info

Product

Resources

About